Reported by Mr. Grassley, without amendment, Ms. Klobuchar (for herself, Mr. Grassley, Mr. Durbin, Mr. Blumenthal, Mr. Cruz, Mr. Welch, and Mr. Booker) introduced the following bill; which was read twice and referred to the Committee on the Judiciary
To enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes.
5 U.S.C. 706(2)(A) 15 U.S.C. 12, 26, 45
and
53 21 U.S.C. 355
and
355 42 U.S.C. 262(k)
Document Citations
Citations are generated automatically from bibliographic data
as a convenience and may not be complete or accurate.
Chicago
U.S. Congress. Senate. Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act. S. 1095. 119th
Cong., 1st
sess., Reported in Senate April 10, 2025. https://www.govinfo.gov/app/details/BILLS-119s1095rs.
APA
Congress, Senate (2025, April 10). Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act (S. 1095 (RS)). Retrieved from https://www.govinfo.gov/app/details/BILLS-119s1095rs.
MLA
United States, Congress, Senate. Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act. U.S. Government Publishing Office, https://www.govinfo.gov/app/details/BILLS-119s1095rs. 119th Congress, S. 1095, Reported in Senate 10 Apr. 2025.
Bluebook
S.1095 - 119th Congress (2025-2026): Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act, S.1095, 119th Cong. (2025), https://www.govinfo.gov/app/details/BILLS-119s1095rs.
